Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial.
The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.
Lederman
R J
RJ
Department of Internal Medicine, Division of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.
Tenaglia
A N
AN
Anderson
R D
RD
Hermiller
J B
JB
Rocha-Singh
K
K
Mendelsohn
F O
FO
Hiatt
W R
WR
Moon
T
T
Whitehouse
M J
MJ
Annex
B H
BH
D004311:Double-Blind Method; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012107:Research Design
D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2